There has never been an effective drug for advanced thyroid cancer – until now. During this weekend's annual meeting of the American Society of Clinical Oncology in Chicago, Marcia Brose, MD, PhD, an assistant professor of Otolaryngology and Head and Neck Surgery and Hematology/Oncology in the Abramson Cancer Center, presented the results of an international Phase III trial for the drug sorafenib among thyroid cancer patients who had stopped responding to standard treatments. The findings showed that sorafenib kept metastatic thyroid cancer in check for nearly 11 months – almost double that of patients who took a placebo. "We've taken a big step with this study," Brose said. "The message for these patients is that there is hope." The findings, which were presented in a plenary session during the ASCO meeting, were covered by news outlets including USA Today, the Wall Street Journal, U.S. News and World Report and the Philadelphia Inquirer (via HealthDay News), MedPage Today, Medscape and others.